| Not Yet Recruiting | Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitax ESCC | Phase 2 | 2026-06-01 |
| Not Yet Recruiting | A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection, Neoadjuvant Immunotherapy | Phase 2 | 2026-05-30 |
| Not Yet Recruiting | A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence HCC - Hepatocellular Carcinoma | Phase 3 | 2026-05-30 |
| Not Yet Recruiting | A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma | Phase 2 | 2026-05-01 |
| Recruiting | Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | 2026-05-01 |
| Not Yet Recruiting | A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metast Malignant Solid Tumor, Brain Metastasis | Phase 2 | 2026-05-01 |
| Not Yet Recruiting | Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin HCC - Hepatocellular Carcinoma | Phase 2 | 2026-04-30 |
| Not Yet Recruiting | Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors | Phase 2 | 2026-04-05 |
| Not Yet Recruiting | Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophag ESCC, Tislelizumab, Chemotherapy | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Can NSCLC | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive Breast Cancer, RWS, Pyrotinib | N/A | 2026-04-01 |
| Not Yet Recruiting | A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Breast Cancer | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adeno GEJ Adenocarcinoma | N/A | 2026-04-01 |
| Not Yet Recruiting | A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadj TNBC | N/A | 2026-03-25 |
| Not Yet Recruiting | A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Eff Brain (Nervous System) Cancers | Phase 1 | 2026-03-20 |
| Recruiting | Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | 2026-03-12 |
| Not Yet Recruiting | A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC Intrahepatic Cholangiocarcinoma | Phase 2 | 2026-03-09 |
| Not Yet Recruiting | Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma) | Phase 2 | 2026-03-01 |
| Recruiting | A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsa BRAF V600E, Colorectal Cancer, Sintilimab | Phase 2 | 2026-03-01 |
| Not Yet Recruiting | Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC NSCLC (Non-small Cell Lung Cancer) | Phase 2 | 2026-02-24 |
| Not Yet Recruiting | Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Inse Breast Cancer | Phase 2 | 2026-02-21 |
| Not Yet Recruiting | Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally RCC, Renal Cell Cancer | Phase 2 | 2026-02-15 |
| Not Yet Recruiting | Adebrelimab Neoadjuvant Treatment for Resectable ESCC ESCC | N/A | 2026-02-15 |
| Not Yet Recruiting | Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for Pancreatic Cancer, Adult | Phase 3 | 2026-02-01 |
| Not Yet Recruiting | Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially BTC | Phase 2 | 2026-02-01 |
| Not Yet Recruiting | A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consol Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage | Phase 2 | 2026-02-01 |
| Not Yet Recruiting | Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperat NSCLC | Phase 2 | 2026-01-30 |
| Recruiting | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | 2026-01-30 |
| Not Yet Recruiting | A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Can Platinum-sensitive, TNBC, Triple Negative Breast Cancer, BRCA1/2 Mutation or Not | Phase 2 | 2026-01-20 |
| Not Yet Recruiting | Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer Pancreatic Cancer Non-resectable | Phase 4 | 2026-01-20 |
| Not Yet Recruiting | Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors NSCLC | Phase 2 | 2026-01-06 |
| Recruiting | Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases | Phase 2 | 2026-01-01 |
| Not Yet Recruiting | Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety St Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib | Phase 2 | 2026-01-01 |
| Not Yet Recruiting | Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Neuroblastoma (NB), Neuroblastoma in Children | Phase 2 | 2025-12-31 |
| Not Yet Recruiting | A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy RCC | — | 2025-12-31 |
| Not Yet Recruiting | A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | 2025-12-25 |
| Recruiting | Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCL Non Small Cell Lung Cancer | Phase 2 | 2025-12-22 |
| Not Yet Recruiting | Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Tota Gastrectomy | Phase 2 | 2025-12-22 |
| Not Yet Recruiting | SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breas SHR-A1811, HER2-Postive Breast Cancer, HR+ Breast Cancer | Phase 2 | 2025-12-20 |
| Not Yet Recruiting | A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients Breast Cancer Patients Treated With T-DXd | Phase 4 | 2025-12-15 |
| Not Yet Recruiting | Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Adva Breast Cancer | Phase 2 | 2025-12-15 |
| Not Yet Recruiting | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induct Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | 2025-12-15 |
| Active Not Recruiting | Prognostic Model of Elderly Hodgkin Lymphoma in China Hodgkin Lymphoma | — | 2025-12-09 |
| Active Not Recruiting | A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Sol Solid Tumors | Phase 1 | 2025-12-04 |
| Recruiting | Serplulimab for Locally Advanced Cervical Cancer Cervical Cancer | Phase 2 | 2025-12-03 |
| Recruiting | WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC NSCLC (Non-small Cell Lung Cancer) | Phase 2 | 2025-12-01 |
| Not Yet Recruiting | Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC TNBC - Triple-Negative Breast Cancer, PD-L1 Positive | Phase 2 | 2025-12-01 |
| Not Yet Recruiting | Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer Lung Cancer | Phase 2 | 2025-12-01 |
| Recruiting | TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadju NSCLC | Phase 2 | 2025-12-01 |
| Not Yet Recruiting | Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Ca Extensive Stage Lung Small Cell Cancer | Phase 2 | 2025-11-01 |
| Recruiting | Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Advanced Colorectal Cancer | Phase 2 | 2025-11-01 |
| Recruiting | A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment Solid Tumors | Phase 1 | 2025-10-16 |
| Not Yet Recruiting | QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therap Cervical Cancer, Cervical Cancer Metastatic, Cervical Cancer Recurrent | Phase 2 | 2025-10-01 |
| Recruiting | An Exploratory Study on Microbial Biomarkers Associated With the Efficacy of Neoadjuvant Therapy Digestive System Malignancies | — | 2025-10-01 |
| Not Yet Recruiting | Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and Mantle Cell Lymphoma | Phase 2 | 2025-10-01 |
| Not Yet Recruiting | Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients Cytotoxic Drugs, Romiplostim N01, Breast Cancer | N/A | 2025-09-20 |
| Not Yet Recruiting | Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cance NSCLC | — | 2025-09-20 |
| Not Yet Recruiting | Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resec Head &Amp; Neck Squamous Cell Carcinoma | Phase 2 | 2025-09-20 |
| Not Yet Recruiting | A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Pati HCC | Phase 2 | 2025-09-10 |
| Not Yet Recruiting | Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatoce Hepatocellular Carcinoma | Phase 2 | 2025-09-10 |
| Not Yet Recruiting | Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Triple Negative Breast Cancer (TNBC), PD-L1 Positive | Phase 2 | 2025-09-01 |
| Recruiting | Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line HCC | Phase 2 | 2025-08-22 |
| Recruiting | The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer Gastric Cancer (GC), No.4sb | — | 2025-08-18 |
| Not Yet Recruiting | Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer Triple Negative Breast Cancer | Phase 1 / Phase 2 | 2025-08-15 |
| Not Yet Recruiting | Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellu Hepatocellular Carcinoma | Phase 2 | 2025-08-01 |
| Not Yet Recruiting | The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcin Hepatocellular Carcinoma (HCC), Real World Study | — | 2025-08-01 |
| Recruiting | DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI Esophageal Cancer | Phase 2 | 2025-08-01 |
| Not Yet Recruiting | RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT, Newly Diagnosed Multiple Myeloma (NDMM) | Phase 1 | 2025-08-01 |
| Enrolling By Invitation | Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast CDK4/6 Inhibitors, Depression Anxiety Disorder, Breast Cancer | N/A | 2025-07-05 |
| Recruiting | Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors Solid Cancers, Radiotherapy, Immune Checkpoint Inhibitor | Phase 2 | 2025-07-01 |
| Not Yet Recruiting | A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/ Relapsed/Refractory Follicular Lymphoma | Phase 2 | 2025-07-01 |
| Not Yet Recruiting | Supermicrosurgical Lymphaticovenous Anastomosis for Prevention of Upper Limb Lymphedema Breast Cancer-Related Lymphedema, Lymphedema, Breast Cancer Invasive | N/A | 2025-07-01 |
| Not Yet Recruiting | BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma Marginal Zone Lymphomas | Phase 2 | 2025-07-01 |
| Not Yet Recruiting | Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC G Gastric Cance | Phase 2 | 2025-07-01 |
| Not Yet Recruiting | Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Ho Triple-Negative Breast Cancer (TNBC) | Phase 2 | 2025-06-30 |
| Not Yet Recruiting | A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 U HER2 Overexpression, Advanced Stage Breast Cancer, Low Expression of HER2 | — | 2025-06-30 |
| Not Yet Recruiting | FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Trea Hepatocellular Carcinoma (HCC) | Phase 2 | 2025-06-30 |
| Recruiting | Real-world Studies of CDK4/6 Inhibitors Breast Cancer | — | 2025-06-01 |
| Not Yet Recruiting | SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites Solid Tumor, Malignant Ascites | Phase 1 / Phase 2 | 2025-05-30 |
| Not Yet Recruiting | Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malig Biliary Tract Cancer | Phase 2 | 2025-05-25 |
| Not Yet Recruiting | A Multicenter Randomized Controlled Clinical Trial of the Impact of Minimally Invasive Abdominal Surgery Esoph PostoperativePulmonaryComplications | N/A | 2025-05-20 |
| Recruiting | Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Refractory | Phase 2 | 2025-05-15 |
| Recruiting | QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer Endometrial Adenocarcinoma, Endometrial Cancer | Phase 2 | 2025-05-01 |
| Not Yet Recruiting | AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer Pancreatic Cancer, Adult | Phase 2 | 2025-04-21 |
| Recruiting | Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Sta NSCLC (Non-small Cell Lung Cancer) | Phase 2 | 2025-04-01 |
| Not Yet Recruiting | Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy Lung Cancer, Small Cell, Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 2 | 2025-04-01 |
| Recruiting | A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma) | Phase 1 | 2025-03-31 |
| Recruiting | A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2025-03-28 |
| Recruiting | A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor Advanced Solid Tumors | Phase 1 | 2025-03-18 |
| Recruiting | QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer Metastatic Pancreatic Cancer | Phase 2 | 2025-03-07 |
| Not Yet Recruiting | Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutan Non-small Cell Lung Cancer | Phase 2 | 2025-03-01 |
| Recruiting | Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC Esophageal Cancer | Phase 2 | 2025-03-01 |
| Recruiting | Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Breast Cancer | Phase 3 | 2025-03-01 |
| Not Yet Recruiting | Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Hepatocellular Carcinoma | Phase 2 | 2025-03-01 |
| Not Yet Recruiting | Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer Esophageal Squamour Cell Cancer | Phase 2 | 2025-03-01 |
| Not Yet Recruiting | Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases Brain Metastasis, SRS | N/A | 2025-03-01 |
| Recruiting | Second-line Immunotherapy for ES-SCLC Extensive Stage Small Cell Lung Cancer (ES-SCLC) | N/A | 2025-02-28 |
| Not Yet Recruiting | The Importance of Thymus Anatomy to the Radical Resection of Thyroid Cancer Surgery and the Protection of Para Thyroid Cancer, Surgery | N/A | 2025-02-20 |
| Enrolling By Invitation | Laparoscopic Staging for Stage III Gastric Cancer Gastric Cancer (GC), Gastric Adenocarcinoma | N/A | 2025-02-01 |
| Recruiting | Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer Primary Liver Cancer | Phase 2 | 2025-01-01 |
| Not Yet Recruiting | A Study of 3D Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Sur Kidney Neoplasms / Surgery, Robotic Surgical Procedures, Imaging, Three-Dimensional / Methods | N/A | 2025-01-01 |
| Recruiting | A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer Advanced Pancreatic Cancers | Phase 1 | 2024-12-25 |
| Recruiting | Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma Follicular Lymphoma | Phase 2 | 2024-12-20 |
| Recruiting | A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer | Phase 2 | 2024-12-06 |
| Not Yet Recruiting | Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine） Advanced and Metastatic NSCLC | Phase 3 | 2024-12-01 |
| Recruiting | Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy f Cervical Cancer | Phase 2 | 2024-12-01 |
| Not Yet Recruiting | Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patie Carcinoma, Non-Small-Cell Lung | Phase 2 | 2024-12-01 |
| Recruiting | Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors Cervical Cancers | Phase 2 | 2024-11-19 |
| Recruiting | AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Pa ESCC, Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | 2024-11-16 |
| Recruiting | Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectabl Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | 2024-11-12 |
| Active Not Recruiting | Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Gallbladder Cancer, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma | Phase 2 | 2024-11-12 |
| Not Yet Recruiting | Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolim Unresectable Biliary Tract Carcinoma | Phase 2 | 2024-10-01 |
| Recruiting | Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resista Lung Cancers, Radiation Treatment for Tumors | Phase 2 | 2024-10-01 |
| Not Yet Recruiting | Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Lung Cryablation Pro Lung Cancer, Thoracic Cancer | N/A | 2024-09-15 |
| Recruiting | Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanc Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2024-09-01 |
| Recruiting | Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second- Colorectal Cancer (CRC) | Phase 2 | 2024-09-01 |
| Recruiting | Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanc Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder Cancer | Phase 2 | 2024-09-01 |
| Recruiting | A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neu Real Time Pressure Controller, Breast Cancer, Albumin Paclitaxel | N/A | 2024-09-01 |
| Not Yet Recruiting | Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER CANCER, BRAEST CANCER, Late Frontline | Phase 2 | 2024-08-01 |
| Recruiting | Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients MCL | Phase 2 | 2024-08-01 |
| Not Yet Recruiting | Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma Hepatocellular Carcinoma | Phase 2 | 2024-07-30 |
| Recruiting | Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Breast Cancer | Phase 2 | 2024-07-25 |
| Not Yet Recruiting | Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Breast Cancer | Phase 2 | 2024-07-15 |
| Not Yet Recruiting | Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer HER 2 Low-expressing Breast Cancer | — | 2024-07-04 |
| Recruiting | The Effect of Serum Ferritin in irAE Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia | N/A | 2024-07-04 |
| Recruiting | AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 2 | 2024-07-01 |
| Recruiting | To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-Small Cell Lung Cancer | Phase 2 | 2024-07-01 |
| Recruiting | A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastr Adebrelimab (SHR-1316), XELOX, GC/GEJC | Phase 2 | 2024-07-01 |
| Not Yet Recruiting | Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma FL | Phase 2 | 2024-07-01 |
| Recruiting | Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC. Esophageal Cancer | Phase 2 | 2024-06-19 |
| Recruiting | Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcit Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | 2024-06-15 |
| Recruiting | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma Peripheral T Cell Lymphoma | Phase 2 | 2024-06-01 |
| Not Yet Recruiting | Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results Refractory Breast Cancer | N/A | 2024-06-01 |
| Not Yet Recruiting | Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemo Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2024-06-01 |
| Unknown | Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Fa Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy | Phase 1 | 2024-06-01 |
| Recruiting | The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia General Anesthesia Gastrointestinal Cancer Surgery | — | 2024-05-15 |
| Not Yet Recruiting | A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Lip Intrahepatic Cholangiocarcinoma | Phase 2 | 2024-05-10 |
| Recruiting | Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory | Phase 1 | 2024-05-09 |
| Recruiting | A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors Mesothelin Positive Tumors | N/A | 2024-05-06 |
| Recruiting | Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Adebrelimab, Hepatocellular Carcinoma | Phase 2 | 2024-05-01 |
| Not Yet Recruiting | Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer Pancreatic Cancer | Phase 2 / Phase 3 | 2024-05-01 |
| Recruiting | A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors Relapsed / Refractory Solid Tumor | Phase 1 | 2024-04-19 |
| Recruiting | Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lu Non-small Cell Lung Cancer, EGFR Activating Mutation, Cell Cycle Deregulation | Phase 2 | 2024-04-09 |
| Not Yet Recruiting | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Ca Pancreatic Cancer | Phase 1 / Phase 2 | 2024-04-01 |
| Unknown | Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC Advanced/Metastatic Colorectal Cancer | Phase 2 | 2024-04-01 |
| Recruiting | Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study Advanced Hepatocellular Carcinoma | Phase 2 | 2024-03-20 |
| Recruiting | Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK) NSCLC | Phase 2 | 2024-03-20 |
| Recruiting | Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）. Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma | Phase 2 | 2024-03-14 |
| Completed | A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients Predictive Cancer Model, Gastric Cancer, Lymph Node Metastasis | — | 2024-02-15 |
| Recruiting | Microwave Ablation With Splenic Artery Occlusion for Secondary Hypersplenism Secondary Hypersplenism | N/A | 2024-01-20 |
| Unknown | Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsit Metastatic Biliary Tract Cancer | — | 2024-01-01 |
| Not Yet Recruiting | A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutrop Non Small Cell Lung Cancer | Phase 2 | 2023-12-31 |
| Recruiting | Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer P Gastric Cancer | Phase 2 | 2023-12-01 |
| Recruiting | Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD- Gastric Cancer | — | 2023-11-10 |
| Recruiting | Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer Gastric Cancer | — | 2023-11-10 |
| Recruiting | Fruquintinib Combined With TAS102 for Advanced Gastric Cancer Gastric Cancer | — | 2023-11-10 |
| Recruiting | Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer Cervical Cancer, Induction Chemotherapy, Immunotherapy | Phase 1 / Phase 2 | 2023-11-01 |
| Unknown | The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer Pancreas Cancer, Chemotherapy | — | 2023-10-07 |
| Recruiting | Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC Esophageal Cancer | Phase 2 | 2023-10-05 |
| Unknown | Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer Extensive-stage Small Cell Lung Cancer | Phase 1 / Phase 2 | 2023-09-01 |
| Completed | A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative Surgery Predictive Cancer Model, Hepatic Metastasis, Gastric Cancer | — | 2023-09-01 |
| Unknown | Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer Advanced Biliary Tract Cancer | Phase 2 | 2023-09-01 |
| Recruiting | A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Head and Neck Cancer | Phase 2 | 2023-09-01 |
| Recruiting | Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure HCC | Phase 2 | 2023-08-31 |
| Enrolling By Invitation | Personalized SBRT in Early-Stage Peripheral NSCLC Early-stage Peripheral Non-small Cell Lung Cancer | Phase 2 | 2023-08-04 |
| Unknown | Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Can Locally Advanced Unresectable Gastric Adenocarcinoma | Phase 2 | 2023-08-01 |
| Unknown | HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma Unrescetable Hepatocellular Carcinoma | Phase 2 | 2023-08-01 |
| Unknown | A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients A Assessing the Current Quality of Life Status of Esophageal Cancer Patients Who Have Undergone Radical Chemoradiotherapy/Radiotherapy and Long-term Survival | — | 2023-08-01 |
| Recruiting | Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invas NSCLC, Radiotherapy, Surgery | — | 2023-08-01 |
| Unknown | Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients PDAC - Pancreatic Ductal Adenocarcinoma | Phase 2 | 2023-07-30 |
| Completed | Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Biopsy Procedure. Abdominal Cancer, Thoracic Cancer | N/A | 2023-07-03 |
| Recruiting | Pre-pectoral Breast Reconstruction With or Without Mesh Prepectoral Breast Reconstruction, TiLOOP Mesh | N/A | 2023-07-01 |
| Active Not Recruiting | Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progre Colorectal Cancer | Phase 1 / Phase 2 | 2023-07-01 |
| Unknown | HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable H Unrescetable Hepatocellular Carcinoma | Phase 2 | 2023-06-20 |
| Unknown | H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis Primary Hepatocellular Carcinoma, Portal Vein Thrombosis | Phase 2 | 2023-06-01 |
| Unknown | The Possible Range of No.12a Lymph Node Dissection of Locally Advanced Gastric Cancer Gastric Cancer, No.12a Lymph Node Dissection | — | 2023-06-01 |
| Active Not Recruiting | Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operativ Pancreatic Cancer | Phase 2 | 2023-05-31 |
| Recruiting | Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junc Gastric Adenocarcinoma | Phase 2 | 2023-05-27 |
| Recruiting | A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemo HR Positive HER2 Negative Advanced Breast Cancer | N/A | 2023-05-16 |
| Not Yet Recruiting | A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Pa Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass, Radiotherapy | Phase 2 | 2023-05-15 |
| Unknown | A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma Predictive Cancer Model, Pancreas Cancer | — | 2023-05-01 |
| Unknown | Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Ca Non Small Cell Lung Cancer Recurrent | Phase 2 | 2023-05-01 |
| Unknown | Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Breast Cancer | Phase 2 | 2023-05-01 |
| Unknown | Single-center, Prospective Study on the Identification and Delineation of Brain and Lung Tumors and At-Risk Or Image Quality and Contouring Accuracy of the Tumor in Radiotherapy | — | 2023-04-28 |
| Recruiting | Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients Advanced Hepatocellular Carcinoma | Phase 2 | 2023-04-27 |
| Unknown | Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis Pancreatic Cancer | Phase 2 | 2023-04-27 |
| Completed | Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carc Resectable Hepatocellular Carcinoma | Phase 2 | 2023-04-24 |
| Active Not Recruiting | Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment Progression Free Survival(PFS) | Phase 2 | 2023-04-12 |
| Recruiting | Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsu Non-small-cell Lung Cancer | Phase 2 | 2023-04-12 |
| Completed | Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients Breast Cancer | Phase 2 / Phase 3 | 2023-04-11 |
| Unknown | Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Gastric Neuroendocrine Carcinoma | — | 2023-04-10 |
| Completed | A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting Squamous Cell Carcinoma of Head and Neck, Chemotherapy Induced Nausea and Vomiting | N/A | 2023-04-02 |
| Not Yet Recruiting | Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Aumolertinib, Anlotinib, TP53 | Phase 2 | 2023-03-31 |
| Unknown | Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Gastric Cancer | Phase 2 | 2023-03-21 |
| Completed | Feasibility Study of Radiation Therapy With Wide Detector 4DCT Scanning for Primary or Metastatic Lung Cancer the Diffenence of Different Detector Row 4DCT，Especially in Artifects，Radiation Dose and Target Volume | — | 2023-03-01 |
| Unknown | Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer Gastric Cancer | Phase 2 | 2023-03-01 |
| Unknown | Minimally Invasive Intrathoracic Esophagogastric Side to Side Anastomosis vs. End to Side Anastomosis Epiphora Due to Insufficient Drainage, Left Side, Epiphora Due to Insufficient Drainage, Right Side | N/A | 2023-03-01 |
| Unknown | Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Re Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis | Phase 2 | 2023-01-20 |
| Enrolling By Invitation | AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH Peripheral T-cell Lymphoma Targeted Therapy | Phase 3 | 2023-01-01 |
| Completed | Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced Diarrhea Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Colon and Rectal Cancer | Phase 2 | 2023-01-01 |
| Unknown | Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer Gastric Cancer | Phase 2 | 2023-01-01 |
| Unknown | Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophagea Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) | Phase 2 | 2022-12-24 |
| Unknown | Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2 Advanced HR+ HER2 Negative Breast Carcinoma | N/A | 2022-12-10 |
| Recruiting | Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations Gastrointestinal Cancer | Phase 2 | 2022-12-02 |
| Unknown | Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer Resectable Biliary Tract Cancer | Phase 2 | 2022-12-01 |
| Unknown | A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy | Phase 1 | 2022-11-25 |
| Active Not Recruiting | A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carci Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy | Phase 1 | 2022-11-24 |
| Unknown | Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carci Hepatocellular Carcinoma | Phase 2 | 2022-11-09 |
| Unknown | HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcin Hepatocellular Carcinoma | N/A | 2022-11-01 |
| Unknown | Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Ca Objective Response Rate (ORR) | Phase 2 | 2022-10-30 |
| Recruiting | Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer Head and Neck Cancer | Phase 2 | 2022-10-20 |
| Recruiting | Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) NSCLC, Stage I | Phase 2 | 2022-10-14 |
| Unknown | Early Detection of Pancreatic Cancer Pancreatic Cancer | — | 2022-10-10 |
| Unknown | A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoa HER-2 Positive Breast Cancer | Phase 3 | 2022-10-08 |
| Unknown | Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic C Resectable Pancreatic Cancer | Phase 2 | 2022-10-01 |
| Unknown | Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy | N/A | 2022-09-30 |
| Completed | Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs at Risk Lung Cancer, Breast Cancer, Esophageal Cancer | — | 2022-09-30 |
| Unknown | Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma Intrahepatic Cholangiocarcinoma | Phase 2 | 2022-09-25 |
| Unknown | Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research Breast Cancer | Phase 2 | 2022-09-13 |
| Unknown | A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breas Breast Cancer | Phase 2 | 2022-09-08 |
| Unknown | Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer | Phase 2 | 2022-09-08 |
| Enrolling By Invitation | Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochlorid Recurrent/Refractory Classical Hodgkin's Lymphoma | Phase 2 | 2022-09-01 |
| Unknown | Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer SCLC, Extensive Stage | Phase 1 | 2022-09-01 |
| Unknown | Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis Colorectal Cancer, Liver Metastasis | Phase 2 | 2022-09-01 |
| Unknown | Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellul Resectable Hepatocellular Carcinoma | Phase 2 | 2022-08-23 |
| Unknown | Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer Non-Small Cell Lung Cancer | Phase 1 | 2022-08-01 |
| Recruiting | A Phase II Study of CRT Combined With QL1706 in ESCC Patients Esophageal Squamous Cell Carcinoma | Phase 2 | 2022-08-01 |
| Unknown | The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Mammary Neoplasms, Human | N/A | 2022-07-20 |
| Unknown | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma | Phase 1 | 2022-07-07 |
| Unknown | Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standa Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Pancreatic Carcinoma | Phase 2 | 2022-07-01 |
| Unknown | PD1 and PARP for Maintenance Therapy in NSLLC Lung Cancer | Phase 2 | 2022-06-20 |
| Unknown | Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Unresectable | Phase 2 | 2022-05-11 |
| Recruiting | Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospect Pancreatic Cancer | Phase 2 | 2022-05-06 |
| Recruiting | Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC Lung Neoplasms, Lymph Node Excision | N/A | 2022-05-01 |
| Unknown | Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury. Drug-Induced Acute Liver Injury | N/A | 2022-05-01 |
| Not Yet Recruiting | An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance | Phase 2 | 2022-05-01 |
| Unknown | Serum Exosomal miRNA Predicting the Therapeutic Efficiency in Lung Squamous Carcinoma Lung Neoplasm, Squamous Cell Carcinoma, Exosomes | — | 2022-04-01 |
| Completed | Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium Immunotherapy, Analgesia, NSCLC | — | 2022-03-22 |
| Unknown | Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves During Thoracoscopic Eso Esophageal Cancer | N/A | 2022-03-01 |
| Completed | Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation Carcinoma, Non-Small-Cell Lung, Bevacizumab, Tyrosine Kinase Inhibitor | Phase 2 | 2022-01-30 |
| Unknown | H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Br Advanced HR+ HER2 Negative Breast Carcinoma | N/A | 2022-01-23 |
| Recruiting | GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma Cholangiocarcinoma | N/A | 2022-01-15 |
| Unknown | Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholang Intrahepatic Cholangiocarcinoma | Phase 2 | 2022-01-13 |
| Active Not Recruiting | A Study on the Impact of Intelligent Nutrition Management on Clinical Outcomes in Chemotherapy Patients With G Gastric (Stomach) Cancer, Esophageal Cancer | N/A | 2022-01-01 |
| Unknown | Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatm Hepatocellular Carcinoma | Phase 2 | 2021-12-01 |
| Recruiting | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYST Esophageal Squamous Cell Carcinoma | Phase 3 | 2021-12-01 |
| Active Not Recruiting | Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy | Phase 2 | 2021-11-07 |
| Unknown | Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients First-line Treatment, Advanced Gastric Carcinoma | Phase 1 | 2021-11-01 |
| Unknown | Granisetron Transdermal Patch System for Prevention of CINV by CapeOX Chemotherapy-induced Nausea and Vomiting | Phase 2 | 2021-10-10 |
| Unknown | Clinical Study on Prevention and Treatment of Pyrotinib Associated Diarrhea With Traditional Chinese Medicine Diarrhea Caused by Antitumor Drugs | Phase 2 | 2021-10-08 |
| Unknown | A Study of OLR in First-line Treatment of Mantle Cell Lymphoma Mantle Cell Lymphoma | Phase 2 | 2021-09-30 |
| Unknown | Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary Potentially Resectable Locally Advanced Malignant Tumors of Biliary System | Phase 2 | 2021-09-17 |
| Unknown | Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC First-line Treatment, Advanced Colorectal Cancer | Phase 2 | 2021-09-01 |
| Completed | SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. Breast Cancer | Phase 2 | 2021-08-02 |
| Recruiting | Breast Mesh Used in Two-staged Breast Reconstruction Breast Cancer, Radiation, Breast Reconstruction | N/A | 2021-08-01 |
| Not Yet Recruiting | Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-sm Resectable Locally Advanced Non-small Cell Lung Cancer | Phase 2 | 2021-08-01 |
| Unknown | Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mu Non Small Cell Lung Cancer | Phase 2 | 2021-08-01 |
| Not Yet Recruiting | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma Lung Adenocarcinoma | Phase 2 | 2021-08-01 |
| Unknown | Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer Gastric Cancer, Perioperative, Sintilimab | Phase 2 | 2021-06-21 |
| Unknown | A One-arm, Prospective Study Comparing the Effects of Different Body Composition on the Survival of Patients U Brief Description of Focus of Study | — | 2021-06-17 |
| Unknown | Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Can Triple Negative Breast Cancer | Phase 2 / Phase 3 | 2021-06-15 |
| Unknown | Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations Immunotherapy, Adjuvant Therapy, Colon Cancer | Phase 2 | 2021-06-01 |
| Unknown | A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | 2021-05-26 |
| Unknown | HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC Hepatocellular Carcinoma | Phase 2 | 2021-05-10 |
| Unknown | Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer Small Cell Lung Cancer Limited Stage | Phase 1 | 2021-05-07 |
| Recruiting | Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Locally Advanced Gastric Adenocarcinoma | Phase 2 | 2021-05-01 |
| Unknown | Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Fa Carcinoma, Non-Small-Cell Lung | N/A | 2021-05-01 |
| Unknown | Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or L HER2+ Early or Locally Advanced Breast Cancer | Phase 2 | 2021-05-01 |
| Unknown | Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 ) ESCC, Adjuvant Treatment, Lymph Node Positive | Phase 2 | 2021-05-01 |
| Unknown | Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcino Resectable Hepatocellular Carcinoma | Phase 2 | 2021-04-30 |
| Unknown | Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancrea Pancreatic Cancer | Phase 2 | 2021-04-22 |
| Unknown | Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neur Refractory or Recurrent Neuroblastoma in Children | Phase 2 | 2021-04-12 |
| Unknown | Study on the Peristaltic Direction of GI Anastomosis in Roux-en-Y Reconstruction Peristaltic Direction, Roux-en-Y Gastrointestinal Anastomosis, Gastric Cancer | N/A | 2021-04-02 |
| Unknown | An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma Af Esophageal Squamous Cell Carcinoma, Progression to PD-1 Antibody | Phase 2 | 2021-04-01 |
| Unknown | Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma Adenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemotherapy, Pembrolizumab | Phase 2 | 2021-04-01 |
| Active Not Recruiting | Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Non-small Cell Lung Cancer Metastatic, First-line Treatment | Phase 2 | 2021-03-31 |
| Recruiting | Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer Pancreatic Cancer | Phase 4 | 2021-03-25 |
| Unknown | Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma Disease-free Survival Rate | Phase 2 | 2021-03-20 |
| Unknown | Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutati Non Small Cell Lung Cancer | Phase 3 | 2021-03-12 |
| Unknown | Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafen Sintilimab, Cetuximab, Regorafenib,Combine,mCRC | Phase 2 | 2021-03-01 |
| Unknown | Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer Non-small Cell Lung Cancer | Phase 2 | 2021-03-01 |
| Unknown | Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer Pancreatic Neoplasms | Phase 2 | 2021-03-01 |
| Unknown | Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squa Esophageal Carcinoma | Phase 2 | 2021-02-19 |
| Unknown | Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer | Phase 2 | 2021-02-08 |
| Completed | Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma Resectable Hepatocellular Carcinoma | Phase 2 | 2021-01-26 |
| Unknown | Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer Cervical Cancer | Phase 2 | 2021-01-01 |
| Recruiting | A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer Gastric Cancer | N/A | 2021-01-01 |
| Completed | Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer HER2-positive Advanced Breast Cancer | Phase 2 | 2021-01-01 |
| Unknown | Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastric Cancer | Phase 2 | 2020-12-15 |
| Unknown | Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy Squamous Cell Carcinoma of Head and Neck | Phase 4 | 2020-12-12 |
| Completed | A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma Non-Hodgkin's B-cell Lymphoma | Phase 1 | 2020-11-27 |
| Unknown | Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma Esophagus Cancer | Phase 2 | 2020-11-26 |
| Unknown | Almonertinib With Chemotherapy in mEGFR NSCLC Non-Small Cell Lung Cancer Metastatic | Phase 2 | 2020-11-19 |
| Unknown | Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Non Small Cell Lung Cancer | Phase 2 | 2020-11-01 |
| Unknown | Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Locally Advanced Cervical Cancer | Phase 2 | 2020-11-01 |
| Unknown | Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy Triple-negative Breast Cancer | N/A | 2020-10-30 |
| Recruiting | TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable, Liver Metastases | N/A | 2020-10-27 |
| Unknown | Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC Early Stage Non-small Cell Lung Cancer | Phase 2 | 2020-09-25 |
| Unknown | Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer | N/A | 2020-09-01 |
| Unknown | Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) Esophageal Squamous Cell Carcinoma, Stage III | Phase 2 | 2020-07-08 |
| Unknown | Prevention and Treatment of Pyrrolitinib-associated Diarrhea Breast Cancer | Phase 2 / Phase 3 | 2020-05-16 |
| Unknown | A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer TTP | Phase 4 | 2020-05-01 |
| Unknown | A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Brea Breast Cancer | — | 2020-04-01 |
| Unknown | Bovine Pericardial Patch and TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction. Implant Breast Reconstruction, TiLOOP® Bra Mesh, Bovine Pericardial Patch | N/A | 2020-01-01 |
| Completed | To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer P Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Enteral Nutrition | — | 2019-12-20 |
| Unknown | PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC Hepatocellular Carcinoma Non-resectable | Phase 2 | 2019-11-14 |
| Unknown | Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis Small Cell Lung Cancer | N/A | 2019-11-10 |
| Unknown | Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresect Unresectable Esophageal Cancer | Phase 2 | 2019-11-01 |
| Unknown | Ear Acupuncture Preventing Delayed Gastric Emptying. Auricular Acupoint Embedding, Pancreaticoduodenectomy, Delayed Gastric Emptying | N/A | 2019-10-10 |
| Unknown | Clinical Application of Nutrition Support Package Before Hepatectomy Liver Neoplasms, Nutrition Therapy, Hepatectomy | N/A | 2019-10-01 |
| Unknown | Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer Small Cell Lung Cancer | Phase 2 | 2019-10-01 |
| Unknown | Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mu Non Small Cell Lung Cancer | Phase 2 | 2019-10-01 |
| Unknown | Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer Gastric Cancer | Phase 2 | 2019-09-26 |
| Unknown | Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study i Breast Cancer, Fulvestrant, Palbociclib | — | 2019-09-13 |
| Unknown | Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EG Non Small Cell Lung Cancer | Phase 2 | 2019-07-31 |
| Completed | Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer. Breast Cancer | — | 2019-07-07 |
| Unknown | Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non Non-squamous Non-small Cell Lung Cancer | Phase 3 | 2019-07-01 |
| Unknown | Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC Non-small Cell Lung Cancer, Second-line Treatment | Phase 1 | 2019-06-01 |
| Unknown | Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma Sarcoma | Phase 2 | 2019-06-01 |
| Unknown | Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorecta Colorectal Cancer | Phase 3 | 2019-06-01 |
| Unknown | Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer IIIB/IIIC/IV Lung Cancer | Phase 3 | 2019-06-01 |
| Unknown | Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NS Non-small Cell Lung Cancer, First-line Treatment | Phase 1 | 2019-06-01 |
| Unknown | Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 2 | 2019-06-01 |
| Unknown | Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma Soft Tissue Sarcoma | Phase 2 | 2019-06-01 |
| Completed | Chemotherapy Combined With Apatinib and PD-1 Antibody Gastric Cancer | Phase 2 | 2019-05-30 |
| Unknown | Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer Gastric Cancer Stage IV | Phase 2 | 2019-05-01 |
| Unknown | Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients Non Small Cell Lung Cancer | Phase 2 | 2019-03-08 |
| Enrolling By Invitation | Outcome of Resection for Colorectal Cancer Laparoscopy | N/A | 2019-02-15 |
| Unknown | PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorect MSI-H Advanced Colorectal Cancer | Phase 2 | 2019-01-01 |
| Active Not Recruiting | Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer Unresectable Hepatocellular Carcinoma | — | 2019-01-01 |
| Unknown | Effect of Radiation and Its Timing on Breast Reconstruction in Chinese Patients Breast Cancer | — | 2019-01-01 |
| Unknown | A Trial of Total Versus Partial Omentectomy for Advanced Gastric Cancer in Gastrectomy Gastric Cancer | N/A | 2019-01-01 |
| Unknown | Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection Cholangiocarcinoma, Gall Bladder Carcinoma | Phase 3 | 2018-12-15 |
| Completed | Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive Non Small Cell Lung Cancer | Phase 2 | 2018-12-01 |
| Unknown | A Efficacy and Safety Study of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients Cervical Intraepithelial Neoplasia, HPV | Phase 2 | 2018-12-01 |
| Unknown | A Study to Compare Efficacy and Safety of DRT VS CRT Plus Surgery in Patients Who Achieved CCR for Esophageal Stage II Esophageal Cancer, Stage III Esophageal Cancer | Phase 3 | 2018-12-01 |
| Completed | Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC. Metastatic Esophageal Squamous Cell Carcinoma | — | 2018-10-13 |
| Unknown | Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC Esophageal Cancer | N/A | 2018-09-17 |
| Unknown | Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients Breast Neoplasms | N/A | 2018-06-16 |
| Unknown | The MDA Test to Differentiate of Benign and Malignant Pulmonary Nodules Pulmonary Nodule, Solitary | — | 2018-05-03 |
| Unknown | The Criteria for Lymph Node Sorting for Pathological Examination in Gastric Cancer Lymph Node Metastases, Gastric Cancer, Exanimation | N/A | 2018-04-01 |
| Unknown | The Exploratory Study of Electroacupuncture in the Treatment of Peripheral Neuropathy Induced by Platinum Base Chemotherapy-induced Peripheral Neuropathy | N/A | 2018-02-10 |
| Unknown | XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC Vitamin D3 | Phase 3 | 2018-02-01 |
| Unknown | Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Adv Esophageal Cancer Stage IIB, Esophageal Cancer Stage III | Phase 3 | 2018-02-01 |
| Completed | The Technical Operations And Standard Clinical Application Protocol of CBBCT in Diagnostic Process of Breast C The Clinical Application Guide of Conebeam Breast CT | N/A | 2018-01-01 |
| Not Yet Recruiting | Neck Dissection vs Radiotherapy for Cervical Metastases in Advanced Hypopharyngeal Cancer Hypopharyngeal Carcinoma | N/A | 2018-01-01 |
| Unknown | XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma Gastric Carcinoma | Phase 3 | 2017-12-20 |
| Not Yet Recruiting | Radiotherapy vs Neck Dissection for Clinical T1/2N0 Supraglottic Cancer Supraglottic Cancer | N/A | 2017-12-20 |
| Unknown | Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Bre Susceptibility, Genetic, Chemotherapy Effect | Phase 3 | 2017-12-01 |
| Unknown | Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma Hepatocellular Carcinoma | N/A | 2017-11-14 |
| Unknown | Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Ca Triple Negative Breast Cancer | Phase 2 | 2017-09-06 |
| Completed | Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC Esophageal Cancer | N/A | 2017-07-19 |
| Unknown | Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer Colon Cancer Liver Metastasis | Phase 2 / Phase 3 | 2017-06-20 |
| Unknown | Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy Soft Tissue Sarcoma, Adult, Stage II | Phase 2 | 2017-05-01 |
| Completed | Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma Soft Tissue Sarcoma, Adult, Stage IIB | Phase 2 | 2017-05-01 |
| Unknown | Methods of Computed Tomography Screening and Management of Lung Cancer Lung Neoplasms, Computed Tomography, Mass Screening | N/A | 2017-05-01 |
| Unknown | Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma Differentiated Thyroid Carcinoma | Phase 2 | 2017-03-22 |
| Unknown | An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric Esophagus Cancer, Stage III, Esophageal Gastric Cardia Type Metaplasia, Esophagus Cancer, Stage IV | Phase 2 / Phase 3 | 2017-03-01 |
| Completed | Radiomics of Immunotherapeutics Response Evaluation and Prediction Solid Tumor, Predictive Cancer Model | — | 2017-01-01 |
| Unknown | Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) Hepatocellular Carcinoma | Phase 2 | 2016-12-01 |
| Unknown | Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metast Anthracycline-pretreated Metastatic Breast Cancer | — | 2016-11-01 |
| Unknown | Effect of Different Anesthetics on the Change of Alarmins in Lung Cancer Patients Receiving Pulmonary Lobectom Carcinoma, Non-Small-Cell Lung | N/A | 2016-10-01 |
| Withdrawn | Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases Thymoma, Autoimmune Disease | — | 2016-10-01 |
| Unknown | Evaluation of Pcv-aCO2 in the Fluid Treatment of Abdominal Tumor Patients After Surgery Abdominal Tumor, Abdominal Infection | N/A | 2016-10-01 |
| Completed | Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing NSCLC | — | 2016-09-27 |
| Unknown | A Phase II Trial to Compare Efficacy and Safety of CRT VS Neo-CRT in Patients Who Achieved CCR for Esophageal Stage II Esophageal Cancer, Stage III Esophageal Cancer | Phase 2 | 2016-09-01 |
| Unknown | A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancrea Metastatic Pancreatic Cancer | Phase 2 | 2016-08-01 |
| Unknown | Retrospective Analysis of Effectiveness and Safety Profile of Anastrozole and Letrozole in HR+ Breast Cancer P Breast Cancer | — | 2016-07-01 |
| Unknown | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung C Non-small Cell Lung Cancer | Phase 2 / Phase 3 | 2016-05-01 |
| Unknown | A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Metastatic Renal Cell Carcinoma | Phase 2 | 2016-05-01 |
| Unknown | PERCIST Criteria for Response Evaluation With Solid Tumors Lung Neoplasms, Breast Neoplasms, Colonic Neoplasms | — | 2016-04-01 |
| Unknown | Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV | Phase 1 | 2016-04-01 |
| Unknown | A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Posto Gastric Cancer | Phase 4 | 2016-04-01 |
| Completed | Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesth Intranasal Dexmedetomidine Breast Cancer Local Anaesthesia | Phase 2 | 2016-01-01 |
| Unknown | Metformin Plus Sorafenib for Advanced HCC Hepatocellular Carcinoma | Phase 2 | 2015-12-01 |
| Unknown | Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer Stage III Prostate Cancer | N/A | 2015-11-01 |
| Unknown | Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer Stage IV Prostate Cancer | N/A | 2015-11-01 |
| Completed | Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Neurotoxicity | Phase 3 | 2015-05-05 |
| Unknown | Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer Breast Cancer | — | 2015-05-01 |
| Completed | Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Can Non-small Cell Lung Cancer, Squamous Cell Carcinoma | Phase 2 / Phase 3 | 2014-12-01 |
| Unknown | Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer Esophageal Cancer | Phase 1 / Phase 2 | 2014-07-01 |
| Unknown | A Trial to Evaluate the Superior Mesenteric Vein (14V) Lymphadenectomy for Distal Advanced Gastric Cancer Gastric Cancer | — | 2014-07-01 |
| Unknown | Molecular Phenotype Changes and Personalized Treatment for CRPC Hormone Refractory Prostate Cancer | N/A | 2014-06-01 |
| Unknown | Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnife Liver Neoplasms | Phase 2 | 2014-05-01 |
| Completed | Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis Head and Neck Cancer | Phase 3 | 2014-05-01 |
| Unknown | Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock Abdominal Infection | Phase 2 / Phase 3 | 2014-05-01 |
| Unknown | Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer Carcinoma Breast Stage IV | — | 2014-04-01 |
| Completed | The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma | — | 2014-01-01 |
| Unknown | Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer Metastatic Breast Cancer | Phase 3 | 2013-12-01 |
| Unknown | Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastri Gastric Cancer | Phase 3 | 2013-12-01 |
| Unknown | Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer Metastatic Breast Cancer | Phase 4 | 2013-12-01 |
| Unknown | Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC Colorectal Cancer | Phase 3 | 2013-11-01 |
| Unknown | Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EG Non-small Cell Lung Cancer | Phase 2 | 2012-10-01 |
| Unknown | Clinical Application of Breast Blood-oxygen Functional Imaging Technology Breast Diseases | — | 2012-09-01 |
| Unknown | A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Osteosarcoma | N/A | 2012-09-01 |
| Unknown | Preoperative Biliary Drainage for the Lower Malignant Obstructive Jaundice Postoperative Complications | Phase 3 | 2012-09-01 |
| Unknown | Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes Gastric Cancer | — | 2012-08-01 |
| Unknown | Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemot Squamous Cell Lung Cancer | Phase 2 | 2012-08-01 |
| Unknown | Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation Non-small Cell Lung Cancer Stage III | Phase 2 | 2012-08-01 |
| Unknown | Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors Malignant Solid Tumors | Phase 1 | 2012-07-01 |
| Withdrawn | Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer Pancreatic Cancer | Phase 2 / Phase 3 | 2012-06-01 |
| Unknown | the Effect of Chinese Herbs to Treat Thyroid Diseases With Different Iodine Intake Thyroid Diseases | Phase 1 / Phase 2 | 2012-06-01 |
| Unknown | Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer Stage IV Gastric Cancer | Phase 1 | 2012-05-01 |
| Unknown | Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients Stomach Cancer | Phase 2 | 2012-05-01 |
| Unknown | External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent After Pancreaticoduodenectomy (EDID Postoperative Fistula, Complications of Surgical and Medical Care: General Terms | Phase 2 | 2012-05-01 |
| Unknown | Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia Nosocomial Pneumonia | Phase 2 / Phase 3 | 2012-03-01 |
| Unknown | Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Small Cell Lung Cancer | Phase 2 | 2012-01-01 |
| Unknown | The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer Breast Cancer | — | 2012-01-01 |
| Unknown | A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Multiple Drug Use | Phase 4 | 2012-01-01 |
| Unknown | Trial of Endostar Combined With CHOPT for T Cell Lymphoma T Cell Lymphoma | Phase 2 | 2011-06-01 |
| Unknown | Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas Carcinoma, Hepatocellular | N/A | 2011-03-01 |
| Unknown | Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patien Non-small Cell Lung Cancer | N/A | 2011-03-01 |
| Unknown | Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas Carcinoma, Hepatocellular | N/A | 2011-03-01 |
| Completed | Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study. Carcinoma, Pancreatic Ductal | — | 2011-01-01 |
| Unknown | Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy Esophageal Cancer | Phase 2 / Phase 3 | 2011-01-01 |
| Completed | Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC Non Small Cell Lung Cancer | Phase 4 | 2010-08-01 |
| Unknown | GWAS Research of Lung Cancer in Tianjin Non-small Cell Lung Cancer, Primary Carcinoma | — | 2010-06-01 |
| Completed | Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC) Non Small Cell Lung Cancer | N/A | 2009-12-01 |
| Unknown | Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction Malignant Biliary Obstruction | — | 2009-12-01 |
| Unknown | Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer Carcinoma, Non-Small Cell Lung | Phase 2 | 2009-10-01 |
| Suspended | Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Canc Non Small Cell Lung Cancer | Phase 2 | 2009-09-01 |
| Completed | Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types Af Esophageal Squamous Cell Carcinoma | — | 2003-03-31 |